RT Journal Article
SR Electronic
T1 Obstructive findings in sarcoidosis, diagnosis and therapies modalities
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3637
VO 40
IS Suppl 56
A1 Jelica Videnovic-Ivanov
A1 Snezana Filipovic
A1 Violeta Vucinic
A1 Vlada Zugic
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P3637.abstract
AB Introduction: Symptoms of respiratory disturbances are common during the course of sarcoidosis. The aim of analysis is to notifie obstructive findings in sarcoidosis. Method: The analyses is restrospective in all incominig patients to the Clinic for lung diseases and tuberculosis CC of Serbia in Belgrade. Results: 127 (8,7%) patients with dry cough and occasionaly dyspnea had the impairent of lung function. The main findings were: FEVl / VC 63,1% in 57- 44,8% patients; in 27-21,1% patients – FEVl / FVC were 55,7%, in 3-2,3% patients FEVl / FVC were 68.7 %. Gender distribution were as followed: 264 (66,2%)Female- Male 135 (33,8%); average ages were 43,32 years. Extrathoracis sarcoidosis involvement were find out in 3 (2.3%) patients (skin, lymph nodes,).Lung and nonpulmonary sarcoidosis is notify in 27 pts and in 97 pts lung were the only sarcoidosis manifestation. Radiographic stadium of lung involvement: I-87(68.5%), II-31(24,4%), III-7%(5,%), IV-1 (0,78%). Acute onset of sarcoidosis is predominatly with average level of ACE: 75.3 U / L. After obtaining the diagnosis of sarcoidosis, inhaled corticosteroides were administered, 160 mcg-daily through 3 months with controls which meansa :ACE and UCa/24h levels, lung function, chest X ray. Regression of symptoms such as dry cough were obtained in 55% patients after the period of 2 months; 45% patients were excluded due to persistence of symptoms seeking prednisone. Conclusion – inhaled corticosteroid have the role in sarcoidosis treatment resolving symptoms such as cough, improvement of FEV1, but the main therapy in most of the patients is still orally administired prednisone.